Abstract
Dry eye disease affects one in five adults, and can significantly impair quality of life. Most patients have mild disease This condition is multifactorial, with an inflammatory component which can markedly worsen the impact on the ocular surface. Meibomian gland dysfunction is extremely common in dry eye disease, and contributes to the inflammatory process Management of mild disease includes identifying and removing precipitants, and symptomatic treatment with artificial tear supplements More advanced disease requires management of underlying ophthalmic and systemic conditions, as well as more aggressive therapies to protect the ocular surface
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
